A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network

Cancer Cell

Volumn 9, Issue 4, 2006, Pages 273-285

  Toledo, Franck ^a,b   Krummel, Kurt A ^a   Lee, Crystal J ^a   Liu, Chung Wen ^a   Rodewald, Luo Wei ^a   Tang, Mengjia ^a   Wahl, Geoffrey M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b CNRS   (France)

Author keywords

CELLCYCLE

Indexed keywords

PROLINE; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE REGULATION; CONTROLLED STUDY; EMBRYO; GENE ACTIVATION; GENE REPRESSION; GENETIC CODE; LETHALITY; MOUSE; MOUSE MUTANT; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN STABILITY; PROTEIN TARGETING; SENSITIVITY ANALYSIS; TRANSACTIVATION;

ANIMALIA;

EID: 33645769536     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.03.014     Document Type: Article

References (52)

1. Baptiste N., Friedlander P., Chen X., and Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 21 (2002) 9-21
2. Berger M., Vogt Sionov R., Levine A.J., and Haupt Y. A role for the polyproline domain of p53 in its regulation by Mdm2. J. Biol. Chem. 276 (2001) 3785-3790
3. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., Bargonetti J., Bartel F., Taubert H., Wuerl P., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 (2004) 591-602
4. Bottger V., Bottger A., Garcia-Echeverria C., Ramos Y.F., van der Eb A.J., Jochemsen A.G., and Lane D.P. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18 (1999) 189-199
5. Brooks C.L., and Gu W. Dynamics in the p53-Mdm2 ubiquitination pathway. Cell Cycle 3 (2004) 895-899
6. Chao C., Hergenhahn M., Kaeser M.D., Wu Z., Saito S., Iggo R., Hollstein M., Appella E., and Xu Y. Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J. Biol. Chem. 278 (2003) 41028-41033
7. Chavez-Reyes A., Parant J.M., Amelse L.L., de Oca Luna R.M., Korsmeyer S.J., and Lozano G. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res. 63 (2003) 8664-8669
8. Chen L., Gilkes D.M., Pan Y., Lane W.S., and Chen J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 24 (2005) 3411-3422
9. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., and Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303 (2004) 1010-1014
10. Danovi D., Meulmeester E., Pasini D., Migliorini D., Capra M., Frenk R., de Graaf P., Francoz S., Gasparini P., Gobbi A., et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell. Biol. 24 (2004) 5835-5843
11. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery Jr. C.A., Butel J.S., and Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 (1992) 215-221
12. Dornan D., Shimizu H., Burch L., Smith A.J., and Hupp T.R. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol. Cell. Biol. 23 (2003) 8846-8861
13. Dumaz N., Milne D.M., Jardine L.J., and Meek D.W. Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. Biochem. J. 359 (2001) 459-464
14. Edwards S.J., Hananeia L., Eccles M.R., Zhang Y.F., and Braithwaite A.W. The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions. Oncogene 22 (2003) 4517-4523
15. Finch R.A., Donoviel D.B., Potter D., Shi M., Fan A., Freed D.D., Wang C.Y., Zambrowicz B.P., Ramirez-Solis R., Sands A.T., and Zhang N. mdmx is a negative regulator of p53 activity in vivo. Cancer Res. 62 (2002) 3221-3225
16. Francoz S., Froment P., Bogaerts S., De Clercq S., Maetens M., Doumont G., Bellefroid E., and Marine J.C. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad. Sci. USA 103 (2006) 3232-3237
17. Gu J., Kawai H., Nie L., Kitao H., Wiederschain D., Jochemsen A.G., Parant J., Lozano G., and Yuan Z.M. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem. 277 (2002) 19251-19254
18. Hengstermann A., Whitaker N.J., Zimmer D., Zentgraf H., and Scheffner M. Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation. Oncogene 17 (1998) 2933-2941
19. Johnson T.M., and Attardi L.D. p53QS: an old mutant teaches us new tricks. Cell Cycle 4 (2005) 731-734
20. Jones S.N., Roe A.E., Donehower L.A., and Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378 (1995) 206-208
21. Kawai H., Wiederschain D., Kitao H., Stuart J., Tsai K.K., and Yuan Z.M. DNA damage-induced MDMX degradation is mediated by MDM2. J. Biol. Chem. 278 (2003) 45946-45953
22. Krummel K.A., Lee C.J., Toledo F., and Wahl G.M. The C-terminal lysines fine-tune p53 stress responses in a mouse model, but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. USA 102 (2005) 10188-10193
23. Lev Bar-Or R., Maya R., Segel L.A., Alon U., Levine A.J., and Oren M. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc. Natl. Acad. Sci. USA 97 (2000) 11250-11255
24. Linares L.K., Hengstermann A., Ciechanover A., Muller S., and Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc. Natl. Acad. Sci. USA 100 (2003) 12009-12014
25. Liu G., Parant J.M., Lang G., Chau P., Chavez-Reyes A., El-Naggar A.K., Multani A., Chang S., and Lozano G. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat. Genet. 36 (2004) 63-68
26. Lowe S.W., Ruley H.E., Jacks T., and Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993) 957-967
27. Mantovani F., Gostissa M., Collavin L., and Del Sal G. KeePin' the p53 family in good shape. Cell Cycle 3 (2004) 905-911
28. Marine J.C., and Jochemsen A.G. Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun. 331 (2005) 750-760
29. McCoy M.A., Gesell J.J., Senior M.M., and Wyss D.F. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation. Proc. Natl. Acad. Sci. USA 100 (2003) 1645-1648
30. Meulmeester E., Maurice M.M., Boutell C., Teunisse A.F., Ovaa H., Abraham T.E., Dirks R.W., and Jochemsen A.G. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol. Cell 18 (2005) 565-576
31. Migliorini D., Denchi E.L., Danovi D., Jochemsen A., Capillo M., Gobbi A., Helin K., Pelicci P.G., and Marine J.C. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol. 22 (2002) 5527-5538
32. Miller F.D., Pozniak C.D., and Walsh G.S. Neuronal life and death: an essential role for the p53 family. Cell Death Differ. 7 (2000) 880-888
33. Montes de Oca Luna R., Wagner D.S., and Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378 (1995) 203-206
34. Nister M., Tang M., Zhang X.Q., Yin C., Beeche M., Hu X., Enblad G., van Dyke T., and Wahl G.M. p53 must be competent for transcriptional regulation to suppress tumor formation. Oncogene 24 (2005) 3563-3573
35. O'Gorman S., Dagenais N.A., Qian M., and Marchuk Y. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. Proc. Natl. Acad. Sci. USA 94 (1997) 14602-14607
36. Okamoto K., Kashima K., Pereg Y., Ishida M., Yamazaki S., Nota A., Teunisse A., Migliorini D., Kitabayashi I., Marine J.C., et al. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol. Cell. Biol. 25 (2005) 9608-9620
37. Parant J., Chavez-Reyes A., Little N.A., Yan W., Reinke V., Jochemsen A.G., and Lozano G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29 (2001) 92-95
38. Pereg Y., Shkedy D., de Graaf P., Meulmeester E., Edelson-Averbukh M., Salek M., Biton S., Teunisse A.F., Lehmann W.D., Jochemsen A.G., and Shiloh Y. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc. Natl. Acad. Sci. USA 102 (2005) 5056-5061
39. Ren J., Shi M., Liu R., Yang Q.H., Johnson T., Skarnes W.C., and Du C. The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. Proc. Natl. Acad. Sci. USA 102 (2005) 565-570
40. Roth J., Koch P., Contente A., and Dobbelstein M. Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain. Oncogene 19 (2000) 1834-1842
41. Sakamuro D., Sabbatini P., White E., and Prendergast G.C. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15 (1997) 887-898
42. Steinman H.A., Sluss H.K., Sands A.T., Pihan G., and Jones S.N. Absence of p21 partially rescues Mdm4 loss and uncovers an antiproliferative effect of Mdm4 on cell growth. Oncogene 23 (2004) 303-306
43. Steinman H.A., Hoover K.M., Keeler M.L., Sands A.T., and Jones S.N. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development. Oncogene 24 (2005) 7935-7940
44. Stommel J.M., and Wahl G.M. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 23 (2004) 1547-1556
45. Sui G., Affar el B., Shi Y., Brignone C., Wall N.R., Yin P., Donohoe M., Luke M.P., Calvo D., and Grossman S.R. Yin Yang 1 is a negative regulator of p53. Cell 117 (2004) 859-872
46. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
47. Venot C., Maratrat M., Dureuil C., Conseiller E., Bracco L., and Debussche L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17 (1998) 4668-4679
48. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 (2002) 594-604
49. Wahl G.M., Stommel J.M., Krummel K.A., and Wade M.A. Gatekeepers of the guardian: p53 regulation by post-translational modification, mdm2 and mdmx. In: Wiman K., and Hainault P. (Eds). 25 Years of p53 Research (2005), Springer, Berlin 73-113
50. Walker K., and Levine A. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA 93 (1996) 15335-15340
51. Xiong S., Van Pelt C.S., Elizondo-Fraire A.C., Liu G., and Lozano G. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc. Natl. Acad. Sci. USA 103 (2006) 3226-3231
52. Zhu J., Jiang J., Zhou W., Zhu K., and Chen X. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene 18 (1999) 2149-2155